AMAG Pharmaceuticals

Altaris Capital Partners, a New York-based healthcare investment firm, acquired AMAG Pharmaceuticals in 2020 for approximately $175 million and now holds voting control. Altaris manages roughly $10 billion in cumulative commitments (per Altaris, 2024) and operates AMAG as a dedicated platform within its healthcare-focused private equity strategy.

AMAG's legacy commercial products included Makena, a preterm-birth therapy that the FDA withdrew in 2023 after confirmatory trials failed to show benefit, and Feraheme, an anemia treatment still on the market. Prior to the Altaris acquisition, AMAG divested its Cord Blood Registry service and the MuGard cancer-support product line as part of a broader restructuring.

AMAG's deal pipeline flows through Altaris Capital Partners, which sources proprietary healthcare transactions through its network of executive operating partners, hospital system relationships, and physician-key-opinion-leader referrals. The firm does not operate an independent business-development function visible to external counterparties — all origination runs through the Altaris platform.

AMAG operates as a private equity-backed operating company, not a family office. Altaris Capital Partners structured the original acquisition as a direct control equity investment, and AMAG functions as a portfolio company with its own management team and board, though Altaris controls capital allocation and acquisition strategy.

AMAG is not known to participate in third-party co-investment syndicates. As an Altaris portfolio platform, the firm focuses on wholly owned acquisitions and add-on consolidations in women's health and specialty pharma, consistent with Altaris's control-equity investment model. Altaris periodically syndicates equity in larger transactions but AMAG has not been observed as a source of LP co-investment slots for external allocators.

AMAG's investment mandate is confined to healthcare, with a specific emphasis on women's health, specialty pharmaceuticals, and related therapeutic verticals. The firm does not invest in digital health or provider services outside its therapeutic mandate, nor does it participate in non-healthcare sectors. Historical reports and deal flow (per public record) show no diversification outside this focus.

The appointment of Linda Lennox as CEO in February 2024 (per AMAG press release, February 2024) signaled that Altaris views AMAG as an ongoing operating platform rather than a temporary holding vehicle. Lennox's background includes commercial leadership roles across specialty pharma, suggesting that organic growth and product-line expansion will complement the platform's inorganic consolidation strategy.